Cambridge Innovation Capital has celebrated an exit as Bicycle Therapeutics successfully lists in the US.

Bicycle Therapeutics, a UK-based developer of treatments for diseases with a high unmet need spun out of research institute MRC Laboratory of Molecular Biology, floated on the Nasdaq Global Market yesterday following a $60.7m initial public offering.
The company issued approximately 4.3 million American Depositary Shares, equivalent to the same number of ordinary shares, priced at $14. Shares dropped to $12 by the end of close yesterday.
Bicycle had initially hoped to raise as much as $86m through…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in